← Eichor
Condition: Recurrent Ewing Sarcoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Ewing Sarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Phase 2 · 6 location(s) · Nationwide Children's Hospital · NCT05135975Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
Phase 1 · 3 location(s) · Peking University People's Hospital · NCT06340204Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/Phase 2 · 10 location(s) · St. Jude Children's Research Hospital · NCT04901702DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
Phase 1/Phase 2 · 1 location(s) · Montefiore Medical Center · NCT06892678Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT04851119Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Phase 1 · 8 location(s) · Amgen · NCT07297979Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sa
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06827717HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT04995003Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Phase 1 · 4 location(s) · Children's Hospital of Philadelphia · NCT06156410
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.